Skip to main content
Defiance International

Published study records

Study records for ARA-290

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

64 study records.

0 evidence-verified · 45 citation-verified · 19 identifier-confirmed · 0 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • In vitro: 6
  • In vivo/preclinical: 31
  • Review/meta-analysis: 3
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type not established · Verification: PMID confirmed at PubMed

  • 2022

Targeting the innate repair receptor axis via erythropoietin or pyroglutamate helix B surface peptide attenuates hemolytic-uremic syndrome in mice.

Frontiers in immunology · 2022

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2021

ARA290 inhibits high glucose-induced apoptosis of NRK-52E cells.

Journal of biological regulators and homeostatic agents · 2021

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2021

Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation.

Cell transplantation · 2021

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2020

Helix B surface peptide reduces sepsis-induced kidney injury via PI3K/Akt pathway.

Nephrology (Carlton, Vic.) · 2020

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2020

Potent Therapy and Transcriptional Profile of Combined Erythropoietin-Derived Peptide Cyclic Helix B Surface Peptide and Caspase-3 siRNA against Kidney Ischemia/Reperfusion Injury in Mice.

The Journal of pharmacology and experimental therapeutics · 2020

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2020

Helix B Surface Peptide Protects Cardiomyocytes From Hypoxia/Reoxygenation-induced Autophagy Through the PI3K/Akt Pathway.

Journal of cardiovascular pharmacology · 2020

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2020

Helix B surface peptide protects against acute lung injury through reducing oxidative stress and endoplasmic reticulum stress via activation of Nrf2/HO-1 signaling pathway.

European review for medical and pharmacological sciences · 2020

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2019

Erythropoietin helix B surface peptide modulates miR-21/Atg12 axis to alleviates cardiomyocyte hypoxia-reoxygenation injury.

American journal of translational research · 2019

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2018

Autophagy and Akt in the protective effect of erythropoietin helix B surface peptide against hepatic ischaemia/reperfusion injury in mice.

Scientific reports · 2018

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2017

The Protective Effects of Helix B Surface Peptide on Experimental Acute Liver Injury Induced by Carbon Tetrachloride.

Digestive diseases and sciences · 2017

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2016

ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability.

Shock (Augusta, Ga.) · 2016

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2016

Helix B surface peptide attenuates diabetic cardiomyopathy via AMPK-dependent autophagy.

Biochemical and biophysical research communications · 2016

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.